Sichuan Goldstone Asia Pharmaceutical (300434) Fundamentals 2026 — P/E 22.5x, Revenue Analysis | SniperIQ
Sichuan Goldstone Asia Pharmaceutical (300434) is a CN-listed Industrials company in Industrial - Distribution with a market capitalization of ¥4.2B, trading at ¥10.38 on the SHZ. This SniperIQ fundamentals page covers Sichuan Goldstone Asia Pharmaceutical's valuation (P/E 22.5x, P/B 1.6x), profitability (net margin 17.1%), revenue (¥1.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sichuan Goldstone Asia Pharmaceutical's market cap?
Sichuan Goldstone Asia Pharmaceutical (300434) has a market capitalization of approximately ¥4.2B, trading at ¥10.38 on the SHZ. Market cap moves with the live share price.
What is Sichuan Goldstone Asia Pharmaceutical's P/E ratio?
Sichuan Goldstone Asia Pharmaceutical's trailing twelve-month P/E ratio is 22.5x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is Sichuan Goldstone Asia Pharmaceutical?
Sichuan Goldstone Asia Pharmaceutical runs a net profit margin of 17.1%, a gross margin of 59.7%, and an operating margin of 19.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sichuan Goldstone Asia Pharmaceutical generate?
Sichuan Goldstone Asia Pharmaceutical reported revenue of ¥1.0B for fiscal year 2025, with net income of ¥132M and earnings per share (EPS) of 0.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sichuan Goldstone Asia Pharmaceutical pay a dividend?
Sichuan Goldstone Asia Pharmaceutical offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sichuan Goldstone Asia Pharmaceutical financially healthy?
Sichuan Goldstone Asia Pharmaceutical carries a debt-to-equity ratio of 0.03x and a current ratio of 2.90x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sichuan Goldstone Asia Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sichuan Goldstone Asia Pharmaceutical (300434) the key facts are: market cap ¥4.2B, P/E 22.5x, revenue ¥1.0B, 52-week range 8.58-13.56. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track Sichuan Goldstone Asia Pharmaceutical's full fundamentals live
Get Sichuan Goldstone Asia Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.